Literature DB >> 11755227

Zonisamide has beneficial effects on Parkinson's disease patients.

M Murata1, E Horiuchi, I Kanazawa.   

Abstract

Zonisamide (ZNS) is a generally well tolerated anticonvulsant that has beneficial effects on Parkinson's disease (PD). ZNS (300 mg/day) given to a patient with PD who incidentally had convulsive attacks, ameliorated the attacks and, surprisingly, his parkinsonian symptoms. We, therefore, carried out an open trial of ZNS on nine patients with PD. Patients were given 50-200 mg/day ZNS in addition to their anti-PD drugs. Seven clearly showed lessening of symptoms, especially wearing-off. We speculate that long lasting activation of dopamine synthesis by ZNS ameliorates parkinsonian symptoms, in particular wearing-off.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11755227     DOI: 10.1016/s0168-0102(01)00298-x

Source DB:  PubMed          Journal:  Neurosci Res        ISSN: 0168-0102            Impact factor:   3.304


  34 in total

1.  A review of the use of zonisamide in Parkinson's disease.

Authors:  Pedro Emilio Bermejo; Buenaventura Anciones
Journal:  Ther Adv Neurol Disord       Date:  2009-09       Impact factor: 6.570

2.  Efficacy and safety of pramipexole in restless legs syndrome.

Authors:  John C Morgan; Kapil D Sethi
Journal:  Curr Neurol Neurosci Rep       Date:  2007-07       Impact factor: 5.081

Review 3.  Therapy for Parkinson's disease: what is in the pipeline?

Authors:  Fabrizio Stocchi
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

4.  Zonisamide in Parkinson's disease: profile report.

Authors:  Lily P H Yang; Caroline M Perry
Journal:  Drugs Aging       Date:  2010-01-01       Impact factor: 3.923

Review 5.  Insights into Computational Drug Repurposing for Neurodegenerative Disease.

Authors:  Manish D Paranjpe; Alice Taubes; Marina Sirota
Journal:  Trends Pharmacol Sci       Date:  2019-07-17       Impact factor: 14.819

6.  Movement disorders in patients taking anticonvulsants.

Authors:  C Zadikoff; R P Munhoz; A N Asante; N Politzer; R Wennberg; P Carlen; A Lang
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-09-29       Impact factor: 10.154

7.  Zonisamide Reduces Withdrawal Symptoms But Does Not Enhance Varenicline-Induced Smoking Cessation.

Authors:  Kelly E Dunn; Taylor F Marcus; Cynthia Kim; Jennifer R Schroeder; Ryan Vandrey; Annie Umbricht
Journal:  Nicotine Tob Res       Date:  2015-10-17       Impact factor: 4.244

Review 8.  Low threshold T-type calcium channels as targets for novel epilepsy treatments.

Authors:  Kim L Powell; Stuart M Cain; Terrance P Snutch; Terence J O'Brien
Journal:  Br J Clin Pharmacol       Date:  2014-05       Impact factor: 4.335

Review 9.  Managing bipolar disorder in the elderly: defining the role of the newer agents.

Authors:  Martha Sajatovic; Subramoniam Madhusoodanan; Nicoleta Coconcea
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 10.  Tyrosine hydroxylase (TH), its cofactor tetrahydrobiopterin (BH4), other catecholamine-related enzymes, and their human genes in relation to the drug and gene therapies of Parkinson's disease (PD): historical overview and future prospects.

Authors:  Toshiharu Nagatsu; Ikuko Nagatsu
Journal:  J Neural Transm (Vienna)       Date:  2016-08-04       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.